Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.
about
Lessons learned from gene expression profiling of cutaneous T-cell lymphomaAHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.Cysteine dioxygenase 1 is a tumor suppressor gene silenced by promoter methylation in multiple human cancers.CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patientsMicroRNA expression in Sezary syndrome: identification, function, and diagnostic potentialNovel approach to gene expression profiling in Sézary syndrome.Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)Epigenetics markers of metastasis and HPV-induced tumorigenesis in penile cancerEctopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphomaTranscriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts.EPHA4 is overexpressed but not functionally active in Sézary syndrome.Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndromeDynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis.Induced Sézary syndrome PBMCs poorly express immune response genes up-regulated in stimulated memory T cellsDifferential expression of cysteine dioxygenase 1 in complex karyotype liposarcomas.Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.Genetic alterations in Sezary syndrome.Cutaneous T-cell lymphomas: a review of new discoveries and treatments.Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?New and established treatment options for mycosis fungoides and Sézary syndrome - an update.Sézary syndrome: old enigmas, new targets.Sézary Syndrome: Clinical and Biological Aspects.The biomarker landscape in mycosis fungoides and Sézary syndrome.Pathobiological properties of the ubiquitin ligase Nedd4L in melanoma.miRNA expression profiling of mycosis fungoides.Cysteine Dioxygenase 1 Mediates Erastin-Induced Ferroptosis in Human Gastric Cancer Cells.E3 ubiquitin ligases in cancer and implications for therapies.BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.Construction of a recombinant eukaryotic expression vector containing gene and its expression in colon cancer cells
P2860
Q26865858-C574C990-9742-47CA-BF12-4D95EF654367Q30010179-34B5222F-46E5-489C-BD4E-70B17A4F576DQ31101539-55EA5B63-A120-41AB-8BC1-5483DF057AB9Q33591741-70B3D68F-A944-49F1-87F3-81EC3562E42CQ34122330-CAFD5A05-3970-49D0-A53D-17FF095CDD8BQ34280027-849E85B9-1DBE-4D5A-BC1E-F869D9FBF7CAQ35022833-4B4AC1D0-7B8C-4D7F-B0E0-006F97E48BC9Q35154365-EB471157-4C0E-4698-A573-356CE7C84405Q35201911-275418FE-4405-48AF-8B94-A7DBED537A5FQ36333534-5CA4C3F2-2FC0-4E8C-89EF-4CCDEF5EF49DQ36544714-BBC55A06-0F66-436C-AF8D-3C280D8B6460Q36626781-BCC9F040-D560-42CE-9BEC-E2A6D50EBC0DQ37232211-093DA1DA-663F-4AB0-A6B6-E092EFA5C0E1Q37591359-A6F5BB57-9634-447E-8CC8-DD00681E50F8Q37694523-D589B9E8-DE42-40F6-979E-0A57A4F26371Q37698501-192C2FEF-8E7E-47BC-B9BC-3D0548BB6E42Q37842481-4A53D982-EBB0-4331-A2D3-A52706702722Q37981969-D2E79489-4689-4E76-B2D3-4A4BAE96D300Q38196931-250BF416-0DC7-4AEA-8FF7-27582E725284Q38216976-996784CC-0E12-408E-8A6B-9CA7DB4D5884Q38772711-64FDD36F-2322-408B-BD0A-6707A7A625CEQ38814744-B86E4B37-F3C1-4A03-863B-4A933F653340Q39023382-9CDEF5E0-0CC3-428E-9642-5C99F5A0D55EQ39031391-099E719B-A73E-43D7-8D33-C94E92746845Q41132620-9D62F716-34AA-4407-8FBD-893E51B54EECQ46260326-C830DC10-E839-4D59-ABFD-885B51F54F3CQ47636038-72017824-F904-44DB-856F-408C9A6F3C71Q52976582-08712724-D2F2-401D-BC63-BF2F60E17A4EQ57817293-176F622F-0F3B-4516-8AD0-AD10BE325702
P2860
Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Sézary syndrome is a unique cu ...... arker molecules CDO1 and DNM3.
@ast
Sézary syndrome is a unique cu ...... arker molecules CDO1 and DNM3.
@en
Sézary syndrome is a unique cu ...... arker molecules CDO1 and DNM3.
@nl
type
label
Sézary syndrome is a unique cu ...... arker molecules CDO1 and DNM3.
@ast
Sézary syndrome is a unique cu ...... arker molecules CDO1 and DNM3.
@en
Sézary syndrome is a unique cu ...... arker molecules CDO1 and DNM3.
@nl
prefLabel
Sézary syndrome is a unique cu ...... arker molecules CDO1 and DNM3.
@ast
Sézary syndrome is a unique cu ...... arker molecules CDO1 and DNM3.
@en
Sézary syndrome is a unique cu ...... arker molecules CDO1 and DNM3.
@nl
P2093
P2860
P356
P1433
P1476
Sézary syndrome is a unique cu ...... arker molecules CDO1 and DNM3.
@en
P2093
Gratchev A
P2860
P2888
P304
P356
10.1038/SJ.LEU.2405044
P577
2007-11-22T00:00:00Z
P5875
P6179
1049360924